KREBS BIOCHEMICALS & INDUSTRIES LTD-$

Add to watch list to get report alerts
BSE Code: 524518       NSE Code: KREBSBIO

Business Profile
Business Profile
Krebs Biochemicals & Industries (KREBSBIO) is engaged in the manufacture of bulk actives, intermediates, active pharmaceutical ingredients (API) and other products. Established in 1991 as a public limited company, the company was earlier known as Krebs Biochemicals and got its present name on Dec. 10, 2003.

The ISO 9001:2000 certified company manufactures Ephedrine HCL, Pseudoephedrine HCL, Lovastatin, Sucralose, Simvastatin, Vitamin-C and other products. It also manufactures sugar and potato chips. The manufacturing units have certification from US FDA and EDQM and total five in number. They are located in the Nellore and Guntur districts, Hyderabad and Visakhapatnam in Andhra Pradesh. A 2.5 MW co-generation power plant has been set up at unit II to meet the in-house steam and power requirements of the process plant.

In FY07, the company entered into a manufacturing agreement with Ranbaxy Laboratories for undertaking a series of exhibit batches for new high value products at its Nellore plant and successfully completed two product campaigns. In January 2008, it signed a manufacturing contract with Germany`s Wacker Chemie AG and also signed a preliminary agreement with it to form a joint venture for the manufacture of various products. The company would hold 49% stake in the joint venture. A co-marketing agreement is in place with Ranbaxy Laboratories to market Lovastatin and Simvastatin in new European and other markets. Tie-ups with major distribution firms in UK, Sri Lanka and India and tie-ups with other private label operations in India and Middle East will boost exports.

The registered office is located at 401/402, Cyber Heights, 4th Floor, Plot No-13, Road No.2, Banjara Hills, Hyderabad-500033, Andhra Pradesh.

Financials
Krebs Biochemicals & Industries registered a loss of Rs 36.3 million for the quarter ended December 2007.
Net sales declined 9.66% to Rs 128.76 million for the quarter ended December 2007 from Rs 142.53 million for the quarter ended December 2006.
Total income dipped 9.76% to Rs 128.81 million from Rs 142.74 million for the quarter ended December 2006.
The loss per share of the company stood at Rs 5.15 for the quarter ended December 2007.

Recent Developments
04-APR-08
The company is running into losses for the last three years and finding it difficult to meet the schedule of payment of installments on term loans in time. To overcome the situation, the company decided to approach the corporate debt restructuring cell with a request to rearrange the loan repayments and reduce immediate liability. In their meeting held on Mar. 05, 2008, the empowered group of the CDR cell considered and approved the reduction of interest rate on term loans to 9% per annum; reduction of interest rate on working capital to 8.5% per annum; conversion of 50% of working capital limits as on Oct. 01, 2007 as working capital term loan; funding of interest on WCTL/FITL/TL from Oct. 01, 2007 to Mar. 31, 2009 at 9% p.a.; repayment of WCTL/FITL/TL in 20 installments commencing from Apr. 1, 2010 and sale of assets of the food division of the company.

Future Plans
Once the sugar unit of the company becomes operational, it would expand into many other organic products based on industrial biotechnology. The demand for bio fuels has enhanced importance of sugar industry. It will increase the turnover and profitability of the company substantially.

Other Information
Annual Reports for KREBS BIOCHEMICALS & INDUSTRIES L
Annual Report YearDownload Annual ReportDownload Report Preview
2022-23
2021-22
2020-21
2019-20
2018-19
2017-18
2016-17
2015-16
2014-15
2013-14
2012-13
2011-12
2010-11
2009-10
2008-09
2007-08
2006-07
2005-06
2004-05
2003-04
2002-03
2001-02
2000-01
1999-00
1998-99
1997-98
1996-97

Please Note: Clicking on the download link will add the report to your downloaded reports. You will be able to download it at any time during the subscription period.

Free reports will not be deducted from your subscription.


Request a Report
Close
Select Year   
Description